CritiTech

Home

company info
	about us management and board of directors scientific advisory board

video

View our
Small Particle
Crystalization Proces:

CritiTech, Inc. conducts research and development into the production and application of fine-particle compounds. The company has expanded its operations to include applications in fine particle API production, coatings, and internal product development.

Recent News & Press Releases

October 27, 2009 :: CritiTech will attend
BioPartnering Europe in Vienna

July 28, 2009 :: CritiTech Announces New Clinical
Trial Site in Witchita, Kansas

June 4, 2009 :: CritiTech Announces New CEO

April 2009 :: SCF/CritiTech Announce NIH/NCI Grant

September 2008 :: Nanotax Collaboration Article

July 31, 2008 :: Phase 1 Trial for Nanotax has
begun at The University of Kansas Cancer Center.

news archive

Current Clinical Trials

Nanotax
(Ovarian Cancer)

Email Updates

Enter your email address to stay informed about current research, events, and more.

*we do NOT share your info with third parties

contact info

CritiTech, Inc.
1321 Wakarusa Dr.
Suite 2102
Lawrence Kansas
66049
USA

ph: 785.841.7120
fax: 785.841.7268
info@crititech.com

downloads
	nanotax product profile (.doc) production of fine particles with ultrasonic energy (PDF) nanotax ovarian cancer mouse model (PDF)

events
	CritiTech will attend BioPartnering Europe, Vienna view our news archive